Irinotecan trials for Pancreatic cancer

All Irinotecan trials · All Pancreatic cancer trials

Phase breakdown

Recruiting trials studying Irinotecan for Pancreatic cancer

• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
  NCT04657068 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 164 locations
• A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
  NCT07024615 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
  NCT05365581 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 46 locations
• A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
  NCT07409272 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 62 locations
• AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer
  NCT07619313 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
  NCT06219941 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 52 locations
• GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
  NCT05391126 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
  NCT06586515 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 104 locations
• NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
  NCT06941857 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
  NCT07214298 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies
  NCT04361708 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
  NCT07621718 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
  NCT06998940 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 274 locations

Common questions

How many trials study Irinotecan for Pancreatic cancer?

13 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.